Advertisement
Advertisement

AMLX

AMLX logo

Amylyx Pharmaceuticals, Inc. Common Stock

14.00
USD
Sponsored
+1.01
+7.78%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

13.99

-0.01
-0.07%

AMLX Earnings Reports

Positive Surprise Ratio

AMLX beat 7 of 16 last estimates.

44%

Next Report

Date of Next Report
Mar 02, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.36
Implied change from Q3 25 (Revenue/ EPS)
--
/
-2.70%
Implied change from Q4 24 (Revenue/ EPS)
-100.00%
/
-34.55%

Amylyx Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, AMLX reported earnings of -0.37 USD per share (EPS) for Q3 25, beating the estimate of -0.45 USD, resulting in a 19.37% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -5.89% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of -0.36 USD, with revenue projected to reach -- USD, implying an decrease of -2.70% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Amylyx Pharmaceuticals, Inc. Common Stock reported EPS of -$0.37, beating estimates by 19.37%, and revenue of $0.00, 0% as expectations.
The stock price moved down -5.89%, changed from $13.24 before the earnings release to $12.46 the day after.
The next earning report is scheduled for Mar 02, 2026.
Based on 12 analysts, Amylyx Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.36 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement